<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097716</url>
  </required_header>
  <id_info>
    <org_study_id>B7981069</org_study_id>
    <secondary_id>2021-003611-25</secondary_id>
    <nct_id>NCT05097716</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide</brief_title>
  <official_title>PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE-DOSE RITLECITINIB (PF-06651600) ON THE PHARMACOKINETICS OF SINGLE-DOSE TOLBUTAMIDE IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the&#xD;
      effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of approximately 12 healthy male and/or female participants will be enrolled in the&#xD;
      study to obtain at least 10 evaluable participants who complete the study. This is an&#xD;
      open-label study not requiring an assessment of efficacy or pharmacodynamics markers, but it&#xD;
      will include pharmacokinetic estimation drug-drug interactions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of tolbutamide</measure>
    <time_frame>pre-dose, at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose in Periods 1 and 2</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf (if data permit, otherwise AUClast) of tolbutamide</measure>
    <time_frame>pre-dose, at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose in Periods 1 and 2</time_frame>
    <description>AUCinf: area under the plasma concentration-time profile from time 0 extrapolated to infinite time;&#xD;
AUClast: area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Baseline to day 28</time_frame>
    <description>Treatment-emergent serious and non-serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Ritlecitinib and tolbutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritlecitinib</intervention_name>
    <description>Ritlecitinib 200 mg provided as four 50 mg oral capsules</description>
    <arm_group_label>Ritlecitinib and tolbutamide</arm_group_label>
    <other_name>PF-06651600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolbutamide</intervention_name>
    <description>Tolbutamide 500 mg provided as one 500 mg oral tablet</description>
    <arm_group_label>Ritlecitinib and tolbutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and/or female participants who are healthy as determined by medical evaluation&#xD;
             including medical history, full physical examination (including BP and pulse rate&#xD;
             measurements), clinical laboratory tests, and 12-lead ECG.&#xD;
&#xD;
          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past/present clinically significant hematological, renal, endocrine, pulmonary, GI,&#xD;
             CV, hepatic, psychiatric, neurological, dermatological or allergic disease (including&#xD;
             drug allergies).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  Infection with hepatitis B or C viruses.&#xD;
&#xD;
          -  Participants with any of the following acute or chronic infections or infection&#xD;
             history: any infection requiring treatment within 2 weeks prior to the start of study&#xD;
             participation; any infection requiring hospitalization or parenteral antimicrobial&#xD;
             therapy within 60 days of the first dose of investigational product; any infection&#xD;
             judged to be an opportunistic infection or clinically significant within the past 6&#xD;
             months of the first dose of investigational product; known active or history of&#xD;
             recurrent bacterial, viral, fungal, mycobacterial or other infections; history of&#xD;
             recurrent localized dermatomal herpes zoster, or history of disseminated (single&#xD;
             episode) herpes simplex or disseminated herpes zoster.&#xD;
&#xD;
          -  History of any lymphoproliferative disorder such as EBV related lymphoproliferative&#xD;
             disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive of&#xD;
             current lymphatic or lymphoid disease.&#xD;
&#xD;
          -  Known presence or a history of malignancy other than a successfully treated or excised&#xD;
             non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in&#xD;
             situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981069</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics (PK)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolbutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

